Evidence map›Paper›PMID 36304076›Full record

ArticleFrontiers in allergy2022

Manufacturing processes of peanut (

Stephanie A Leonard, Yasushi Ogawa, Paul T Jedrzejewski, Soheila J Maleki, Martin D Chapman, Stephen A Tilles, George Du Toit, S Shahzad Mustafa, Brian P Vickery

Open access · goldAbstract read
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Effects of Food Processing on Allergenicity.Current allergy and asthma reports · 2025
    Review
  4. Review
  5. Peanut (The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Stephanie A LeonardDivision of Pediatric Allergy / Immunology, University of California San Diego, Rady Children's Hospital, San Diego, CA, United States.
Yasushi OgawaMedical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States.
Paul T JedrzejewskiMedical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States.
Soheila J MalekiUnited States Department of Agriculture, Agricultural Research Service, New Orleans, LA, United States.
Martin D ChapmanPresident / CEO, InBio, Charlottesville, VA, United States.
Stephen A TillesMedical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States.
George Du ToitDepartment of Pediatrics, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
S Shahzad MustafaRochester Regional Health, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States.
Brian P VickeryDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Nestlé Health Science (United States)Agricultural Research Service · USEmory University · USGuy's and St Thomas' NHS Foundation Trust · GBUnity Health System · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Important components of drug safety, efficacy, and acceptability involve manufacturing and testing of the drug substance and drug product. Peanut flour sourcing/processing and manufacturing processes may affect final drug product allergen potency and contamination level, possibly impacting drug safety, quality, and efficacy. We describe key steps in the manufacturing processes of peanut ( Methods: Established criteria for source material must be met for manufacturing PTAH drug product. Degree of roasting was determined with a Hunter colorimeter. Protein/allergen content, identity, potency, safety, and quality of each batch of PTAH drug substance were assessed with a combustion analyzer, allergen-specific Western blot (immunoblotting), ELISA, and HPLC. Contaminants (ie, aflatoxin) were measured by UPLC. Results: Roasting degree beyond "light roast" was associated with variable degrees of protein allergen degradation, or potentially aggregation. Relative potency and amounts of protein allergens showed variability due in part to seasonal/manufacturing variability. Proportion of lots not meeting aflatoxin limits has increased in recent years. Up to 60% of peanut flour source material failed to meet screening selection acceptance criteria for proceeding to drug substance testing, mostly because of failure to meet potency acceptance criteria. Other lots were rejected due to safety (ie, aflatoxin) and quality. Influence of potency variation, within specification parameters, on safety/tolerability observed in trials was considered low, in part due to stringent controls placed at each step of manufacturing. Conclusions: Extensive variability in allergen potency is a critical issue during immunotherapy, particularly during OIT initial dose escalation and up-dosing, as it may result in lack of efficacy or avoidable adverse allergic reactions. Based on EU and US regulatory requirements, the production of PTAH includes manufacturing controls to ensure drug product safety, potency, and quality. For example, although PTAH contains all peanut allergens, each lot has met strict criteria ensuring consistent allergenic potency of Ara h 1, Ara h 2, and Ara h 6. The rigor of PTAH's manufacturing process ensures reliable dose consistency and stability throughout its shelf life.

Indexed as

drugfoodmanufacturingoral immunotherapypeanut allergypeanut (Arachis hypogaea) allergen powder-dnfpstandardization

Identifiers

PMID36304076
PMCPMC9592818
OpenAlexW4304166118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.